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Abstract This paper describes the development and char-
acterization of starch microspheres for being used as drug
delivery carriers in tissue engineering applications. The de-
veloped starch microspheres can be further loaded with spe-
cific growth factors and immobilized in scaffolds, or admin-
istrated separately with scaffolds. Furthermore and due to
the processing conditions used, it is expected that these mi-
crospheres can be also used to encapsulate living cells. The
aim of this study was to evaluate the efficacy of this method-
ology for further studies with biologically active agents or
living cells. The starch microspheres were prepared using
an emulsion crosslinking technique at room temperature to
allow for the loading of biologically active agents. A prelim-
inary study was performed to evaluate the incorporation of
a model drug (nonsteroidal anti-inflammatory drug-NSAID)
and investigate its release profile as function of changes in
the medium parameters, such as ionic strength and pH. The
developed starch-based drug delivery system has shown to be
dependent on the ionic strength of the release medium. From
preliminary results, the release seems to be pH-dependent
due to the drug solubility. It was found that the developed
microspheres and the respective processing route are appro-
priate for further studies. In fact, and based in the process-
ing conditions and characterization, the developed system
present a potential for the loading of different growth fac-
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tors or even living cells on future studies with these systems
for improving bone regeneration in tissue engineering, espe-
cially because the crosslinking reaction of the microspheres
takes place at room temperature.
1. Introduction
There are multiple clinical reasons to develop bone tissue-
engineering alternatives in order to improve the quality of
life of patients. There is a clear need of better scaffold mate-
rials and cell-loaded constructs that can be used in the regen-
eration/engineering of large orthopaedic defects. The main
factors necessary to make a tissue engineering approach suc-
cessful are, in a very simplistic way [1]: (i) scaffolds (ii)
cells, and (iii) growth factors. As a simple description, it is
necessary a scaffold as a support on which cells (after their
isolation and expansion) can be seeded and then will prolif-
erate and differentiate into the aimed phenotype. In addition,
growth factors are required to improve cell differentiation
and proliferation and then achieve tissue regeneration. The
controlled release concepts can be inherent and be a potential
assistant in the three main factors [2]. Referred to above, the
‘traditional’ drug delivery approach can be further applied in
tissue engineering to encapsulate living cells for incorpora-
tion within the scaffolds. In turn, scaffolds can be designed
as ‘traditional’ drug delivery carriers to control a site-and
time-specific release profile of biologically active agents and
also to protect the growth factor.
In our point of view, biodegradable microspheres that can
be used as controlled release systems are a key issue for the
development of an optimal strategy for tissue engineering
applications. The basic idea to try to accomplish in tissue
engineering applications is that biodegradable microspheres
can be either simply injected at the site of regeneration
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together with the scaffolds or coupled/immobilized into or in
the surface of the porous scaffold. Nevertheless, the devel-
oped starch microspheres can be used as ‘traditional’ drug
delivery systems to local delivery of bioactive agents. Starch-
based systems is very promising for several biomedical ap-
plications [3–16], including drug delivery carriers [17–20].
However, up to date there is no information that starch micro-
spheres have been used for this propose. On the other hand,
biodegradable starch-based microspheres have been widely
investigated and even used for a long time as ‘traditional’
drug delivery systems [21–23].
The ability of polysaccharides to form a network struc-
ture (gel), even at very low concentrations, constitutes one of
their most important functional properties. The formation of
a 3D network structure (gelation) offers an effective means
of increasing the chemical stability and mechanical proper-
ties of the system [24, 25]. A wide range of modification
mechanisms that can be applied to starches is known [24,
25]. These include self-association (induced by changes in
pH, ionic strength or physical and thermal means), com-
plexation with salts and covalent crosslinking as used in
the present study. Furthermore, starch is appealing to the
area of drug delivery as it allows to produce systems of
a low toxicity that are biodegradable and very stable [26].
Obviously, it is important to emphasize the high availabil-
ity of starch and remember its renewable origin. In fact,
starch is the most abundant reserve polysaccharide of the
plant kingdom. Therefore, the cost-effectiveness of starch-
based products is another important attractive for the use of
starch in the drug delivery field as well as in other biomedical
applications.
In particular, starch microspheres have been widely in-
vestigated for different drug delivery applications [21–23,
26, 27]. For instances, Illum et al. [26] reported on bioad-
hesive microspheres that could not be cleared easily from
the nasal cavity. The half-life of clearance for starch micro-
spheres was in the order of 240 min as compared to 15 min for
the control formulations. If gentamycin was administrated in
combination with starch microspheres, a significant increase
in bioavailability was obtained [26]. Another example is the
magnetic starch microspheres developed by Fahlvik et al.
[23, 28] for parenteral administration of magnetic iron ox-
ides to enhance contrast in magnetic resonance imaging. This
could be an interesting processing route to be used in the fu-
ture to try to develop magnetic-responsive controlled systems
for delivery of biological active substances.
The use of a particulate embolic agent combined with re-
gional chemotherapy now in clinical use in the treatment liver
cancer has been widely investigated [21]. In this treatment,
degradable starch microspheres (DSM) play an important
role. Furthermore, Bjork et al. [22, 29] reported the use of
these microspheres as nasal delivery systems for drugs such
as insulin.
Concerning the oral administration is important to note
that native starch is almost completely broken down after
oral ingestion [30, 31]. This is done by pancreatic enzymes
that lead to the subsequent absorption from the small intes-
tine into the systemic circulation. A certain proportion of
starch, called resistant starch, escapes digestion in the small
intestine and undergoes fermentation by bacteria in the colon
[32, 33]. However, the enzymatic degradation taking place
in the stomach needs to be controlled to achieve an adequate
delivery of the bioactive agents. With this aim, Larionova
et al. [34] developed crosslinked starch-protein microcap-
sules containing proteinase inhibitor in order to allow for
the oral administration of the proteic or peptide drug. The
protective effect of microcapsules with aprotinin for bovine
serum albumin was revealed in vitro [34].
As it is possible to conclude from the previous observa-
tions, there have been a number of applications of starch
microspheres in the drug delivery field. The present paper
describes the development and characterization of starch mi-
crospheres for drug delivery applications. The microspheres
were prepared using an emulsion crosslinking technique.
A preliminary study was performed to evaluate the incor-
poration of a model drug (nonsteroidal anti-inflammatory
drug-NSAID) and investigate its release profile in function
of changes in the medium parameters. The idea is to develop
systems that might be used in tissue engineering applications,
where the starch microspheres can be either simply injected
at the site of regeneration simultaneously with the scaffold or
coupled with/into the porous scaffold. Furthermore and due
to the processing conditions used, it is expected that these
microspheres can be also used to encapsulate living cells.
2. Materials and methods
Paselli (II) from Avebe (The Netherlands) which is a modi-
fied potato starch was used in this study. As it is well known,
native starch is not soluble in water below 80◦C. This can be a
clear disadvantage in some reactions. To overcome this disad-
vantage, native starch is partially hydrolyzed being modified
into several modified starches, such as Paselli (II), which is
a water-soluble starch. Trisodium trimetaphosphate (TSTP)
was used as starch crosslinking agent Span 80 and Tween
80 were used as hydrophobic and hydrophilic surfactants,
respectively. All the reagents were purchased to Fluka and
used as received.
The drug used in this study was meclofenamic sodium
salt (MS) which is a non-steroidal anti-inflammatory drug
(NSAID) mainly used for the treatment of arthritic inflam-
mations (osteo and rheumatoid). The drug was approved by
the United States’ Food and Drug Administration (FDA) for
the treatment of mild-to-moderate pain in August 1988 [35].
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Fig. 1 Schematic representation of single emulsion crosslinking tech-
nique.
Previously this drug has been incorporated into porous
starch-based drug delivery carriers [17].
For the production of starch microspheres a single emul-
sion crosslinking technique was used. A scheme of the proce-
dure is presented in Fig. 1. Briefly, the water-soluble starch
(25% wt) and the crosslinker agent (5% wt) are dissolved
in the water phase under constant stirring at room temper-
ature in a glass beaker. A mechanical stirrer coupled to the
assembly controls the stirring.
The water-phase (w) and the oilic-phase (o) are mixed
(1:1), using (or not) a hydrophobic surfactant (5% wt), de-
pending on the selection of reaction conditions. After this
step, a w/o emulsion is obtained. The crosslinking reac-
tion is started by raising the pH to a 12-13 value with a
NaOH solution (2% wt) to activate the crosslinking agent,
maintaining the stirring at constant rate. Samples were col-
lected to control the crosslinking reaction at different pe-
riods. When the collected sample is crosslinked, the reac-
tion is stopped by means of neutralizing with HCl solution.
In order to obtain the microspheres, the phases are separated
at the end of the reaction with ethanol. The reaction product
is then decanted or centrifuged (depending on the micro-
spheres size) and washed, repeating this step several times
until total clearance of the oilic-phase. (Note: all the weight
percentages indicated are relative to the water-phase).
In order to load the starch microspheres with the bi-
ologically active substance (2.5% wt), a double emulsion
crosslinking technique is used as represented in Figure 2.
The main difference on the processing route is that it is first
obtained a drug/w emulsion by adding a hydrophilic surfac-
tant. All the sequence of procedure is similar to the one for
single emulsion technique and for that reason it will not be
repeated herein.
In the particular case of starch microspheres, the stirring
and the presence of surfactant was varied to study its effect
on particle size. Table 1 summarizes the conditions for each
crosslinking reaction and the respective sample designation
which will be used for further discussion in this paper.
Table 1 Designation of starch microspheres according the crosslink-
ing reaction conditions.
Designation Surfactant Stirring Rate (rpm)
S1 Yes 1200
S2 Yes 700
S3 No 700
The developed starch-based microspheres were morpho-
logically characterized by Scanning Electron Microscopy
(SEM), in a Leica Cambridge S360. All the samples were
previously gold coated. The SEM analysis allowed for the
characterization of the morphology of the developed micro-
spheres, to evaluate qualitatively the particle size and par-
ticle size distribution. Furthermore, it was used to identify
any morphological changes after release tests. Optical mi-
croscopy was also used to follow the morphology during the
crosslinking reaction using an Eclipse E400 optical Nikon
microscope and images were recorded with a Nikon FDX-
35 camera coupled to the optical microscope.
The particle size and particle size distribution were ac-
cessed in a Coulter LS 230 light scattering particle size ana-
lyzer by saturation in a dispersion of water.
The X-ray diffraction (XRD) spectra were acquired in a
Philips X’Pert MPD diffractometer in order to characterized
structurally the different particles developed as well as the
main raw materials used.
In vitro drug release tests were carried out for starch drug-
loaded microspheres at physiological temperature (T = 37
± 1◦C). Solutions with different salt concentrations [NaCl –
0 M, 0.154 M (physiological value) and 1 M] were used in
order to increase ionic strength of the release medium and
study this medium parameter in the release profile. Starch-
loaded particles were placed in containers carefully sealed
with test solution for periods up to 14 days. At different
time periods, solution aliquots of 5 ml were colleted, and the
same initial volume was adjusted with new fresh solution.
The drug release was measured by UV spectrophotometry in
a Shimadzu UV-1603 spectrophotometer taking the original
test solution as reference.
3. Results and discussion
By optical microscopy it was possible to follow the crosslink-
ing reaction. As shown in Fig. 3.a after 2 h of crosslinking
Fig. 2 Schematic representation
of double emulsion crosslinking
technique.
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Fig. 3 Optical micrographs
showing the evolution of
emulsion crosslinking reaction
after (a) 2 h and (b) 6h.
reaction the starch microspheres were not totally formed. Af-
ter 6h of reaction time, the starch microspheres shown to be
morphologically stable and crosslinked. This reaction time
was selected based in the study of the reaction progress at
several time periods. The 6h reaction period was the optimal
time in terms of crosslinking and morphological stability of
the starch microspheres. This value for reaction time was
set and used in all reactions based in optical microscopy ob-
servations and following the crosslinking reaction by collect-
ing several samples at several periods performing dissolution
tests that shown that at this reaction time the starch particles
were stable.
The morphology of the developed starch microspheres
was accessed by SEM and it is shown in Fig. 4. It is possi-
ble to observe that the developed processing route allowed
obtaining dense and approximately spherical microspheres.
By light scattering analysis it was possible to determine
the particle size and particle size distribution as it is shown
in Fig. 5. The emulsion crosslinking technique allowed for
the controlled production of microspheres with a high array
of mean diameters ranging from 3 to 540 μm by changing
the reaction parameters. By using this characterization tech-
nique, it was possible to evaluate the effect of the different
processing conditions studied, namely the influence of sur-
factant and stirring rate, in the microspheres size. It can be
seen that the influence of surfactant is of major importance in
the control of particle size since it was possible, with the use
of surfactant, to decrease the microspheres mean diameter
from 500 μm (S3) to 30 μm (S2). This is due to the decrease
of interfacial energy between the polymeric phase and the
crosslinking medium by the surfactant presence, allowing
the stabilization of the pre-formed microspheres to maintain
their size until completion of the crosslinking reaction.
The stirring rate also allowed a significant decrease in
particle size by decreasing the mean diameter from 30 μm
(S2) to 3 μm (S1). This parameter was also very effective
since it is known that is rather difficult to decrease particle
size below a certain small diameter due to the pre-formed
Fig. 4 SEM micrographs
showing the
starch-microspheres
morphology. (Please note the
respective scale bars).
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Fig. 5 Particle size and
distribution of starch
microspheres as function of
different reaction conditions (S1
– surf., ↑ rpm; S2 – surf., ↓ rpm;
S3 – No surf., ↓ rpm). Please
see Table 1 for more details.
microspheres stabilization. The influence of both the stirring
rate and the presence and concentration of surfactant was
already studied to have influence in the microparticles mean
diameter [36].
X-ray diffraction was used to accessed the structural char-
acterization of the developed starch microspheres and evalu-
ate the influence of the processing route in the particles final
composition. As it is possible to see in the XRD diffrac-
tograms shown in Fig. 6, there was an incorporation of
sodium phosphate in the developed particles due to the se-
lected processing route. This fact can be related to the pres-
ence of residual crosslinking agent.
In vitro release tests were carried out for starch micro-
spheres with higher diameter (500 μm) in order to minimize
sampling problems, since the aim of this study was to evalu-
ate the influence of ionic strength and pH of release medium
on the drug release. Nevertheless, it is expected that smaller
microspheres show a similar release pattern with increased
initial drug release due to higher surface area that leads to a
higher water uptake. In initial release periods, the water up-
Fig. 6 XRD diffractograms of starch microspheres obtained by emul-
sion crosslinking technique. Please note that (•) correspond to sodium
phosphate.
take is the controlling mechanism since starch microspheres
have a hydrophilic character.
From previous experiences it was concluded that the sol-
ubility of MS decreases strongly with decreasing pH and
for this reason the particles were not neutralized prior to re-
lease tests. The pH of the release medium is defined from
the NaOH concentration in the particles and solution, being
9.0 ± 0.2. An extra small amount of NaOH was added to the
release medium in two release conditions in order to increase
the initial pH medium value (up to 10 ± 0.2), facilitating the
initial drug solubilization. For initial release periods, this in-
crease in the pH value seemed to have no significant effect
since, the release is very fast in the first 2 hours (Fig. 7) for
all the studied mediums. Nevertheless, and comparing the
mediums with the same salt concentration for higher release
periods, the increase in the pH increments in some extent
the drug release. One can concluded that the lower pH value
(pH = 9.0 ± 0.2) is not compromising the MS dissolution
being high enough to dissolve all the MS released. Having in
consideration the lower MS solubility at lower pHs, it is ex-
pected that, in an in vivo application, the initial burst release
will be decreased due to the physiological pH value. Further
studies with significantly different pH values are needed in
order to be possible to undoutebouly classify theses systems
as pH-dependent.
Fig. 7 MS release profile of starch loaded microspheres as function of
release medium.
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It was possible to confirm that the release of the drug
shown to be strongly dependent on salt concentration as it
can be observed in the data plotted in Fig. 7 for different
salt concentrations mediums. This can be attributed to the
dependence of drug solubility and swelling behavior of the
starch particles on the medium ionic strength. These param-
eters will control the MS release being possible to classify
the developed starch-MS systems as responsive drug delivery
systems in terms of ionic strength-dependence. This behav-
ior has obvious advantages in in-vivo applications to main-
tain the balance of salt in cases for instances of perspiration.
These systems can respond to a decrease or increase in the salt
concentration releasing the appropriated bioactive agent pre-
viously incorporated to reestablish the equilibrium. In terms
of bone tissue engineering, the equilibrium of salt concen-
tration is of major importance for instances to maintain cells
viability.
4. Conclusions
The single emulsion crosslinking technique allowed for the
production of spherical starch microspheres with a high array
of mean diameters ranging from 3 to 540 μm with a narrow
size distribution for smaller diameters. This was achieved by
varying the conditions of crosslinking reaction being demon-
strated that the particles size can be controlled by means of
changing the processing conditions. Concerning the initial
release of drug from the starch microspheres it was possible
to observe that the delivery is very fast in the first 2 hours and
independent of medium conditions. For higher release peri-
ods, the increase in the pH increases in some extent the drug
release, independently of salt concentration. Concerning the
influence of medium ionic strength, it was demonstrated that
the drug release was strongly dependent on salt concentra-
tion, being possible to classify this system as ionic strength
dependent.
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